- The report introduces two key tracking indicators: "Large Order Transaction Amount Proportion" and "Net Active Buy Amount Proportion" [7] - The "Large Order Transaction Amount Proportion" is designed to capture the buying behavior of large funds. It is calculated by identifying large orders from transaction data and computing the proportion of large buy orders' transaction amounts relative to the total daily transaction amount [7] - The "Net Active Buy Amount Proportion" reflects investors' active buying behavior. It is derived by distinguishing active buy and sell transactions from transaction data, calculating the net active buy amount (active buy amount minus active sell amount), and expressing it as a proportion of the total daily transaction amount [7] Factor Backtesting Results - For individual stocks, the top 10 stocks with the highest 5-day average "Large Order Transaction Amount Proportion" include Xinhua Du (90.6%, 99.2% percentile), Beichen Industrial (89.1%, 98.8% percentile), and Zhongyou Engineering (88.8%, 100.0% percentile) [9] - For individual stocks, the top 10 stocks with the highest 5-day average "Net Active Buy Amount Proportion" include Senying Windows (22.3%, 100.0% percentile), Huitong Group (20.0%, 100.0% percentile), and Yuandong Biotech (19.6%, 100.0% percentile) [10] - For broad-based indices, the 5-day average "Large Order Transaction Amount Proportion" ranges from 71.7% (Shanghai 50 Index) to 74.3% (China Securities 500 Index), while the "Net Active Buy Amount Proportion" ranges from -5.2% (Shanghai 50 Index) to 1.9% (China Securities 500 Index) [12] - For industries, the 5-day average "Large Order Transaction Amount Proportion" is highest in the banking sector (80.6%, 86.5% percentile) and lowest in the electronics sector (70.8%, 16.4% percentile). The "Net Active Buy Amount Proportion" is highest in the steel sector (7.9%, 75.8% percentile) and lowest in the banking sector (-14.6%, 3.3% percentile) [13] - For ETFs, the top 10 ETFs with the highest 5-day average "Large Order Transaction Amount Proportion" include Guotai CSI A500 ETF (92.3%, 36.1% percentile) and Guotai SSE 10-Year Treasury Bond ETF (90.7%, 89.3% percentile) [15] - For ETFs, the top 10 ETFs with the highest 5-day average "Net Active Buy Amount Proportion" include Southern SSE STAR Chip ETF (27.5%, 100.0% percentile) and E Fund Hang Seng Dividend Low Volatility ETF (23.6%, 99.6% percentile) [16]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., successfully passed the FDA's pre-approval inspections for its Naloxone nasal spray product with zero deficiencies [1][2]. Group 1: Inspection Details - The FDA inspections took place from May 6 to 9 and May 16 to 22, 2025, focusing on current Good Manufacturing Practices (cGMP) and BioResearch Monitoring (BIMO) [1]. - The inspections were conducted for the Naloxone nasal spray product, specifically on the nasal spray production line [1]. - The inspection concluded with a zero deficiency report (no 483), indicating compliance with FDA standards [1]. Group 2: Product and Company Impact - This inspection marks the second time ShuoDe Pharmaceutical has undergone an FDA inspection and the first for its nasal spray production line [1]. - The successful inspection is expected to expedite the approval process for the company's submitted Abbreviated New Drug Applications (ANDA) in the U.S. and support the implementation of its internationalization strategy [1].

Core Viewpoint - The company, Yuandong Biotech (688513.SH), announced that its wholly-owned subsidiary, Chengdu Shode Pharmaceutical Co., Ltd., successfully passed FDA inspections for its naloxone nasal spray, receiving zero deficiencies in the reports [1] Group 1 - The FDA conducted current Good Manufacturing Practice (cGMP) inspections and Bioresearch Monitoring (BIMO) inspections from May 6 to May 9 and May 16 to May 22, 2025 [1] - The inspections were part of the approval process for the naloxone nasal spray [1] - Chengdu Shode Pharmaceutical received two Establishment Inspection Reports (EIR) from the FDA, indicating compliance with regulatory standards [1]

Core Viewpoint - The company, Yuandong Biotech (688513.SH), announced that its wholly-owned subsidiary, Chengdu Shode Pharmaceutical Co., Ltd., successfully passed FDA inspections for the production of Naloxone nasal spray with zero deficiencies [1] Group 1 - The inspections conducted by the FDA included Current Good Manufacturing Practice (cGMP) and Bioresearch Monitoring (BIMO) [1] - The inspections took place from May 6 to May 9 and May 16 to May 22, 2025 [1] - The company received two Establishment Inspection Reports (EIR) from the FDA confirming the successful inspections [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its subsidiary, Shuo De Pharmaceutical, received two on-site inspection reports from the US FDA, passing with zero deficiencies, which indicates compliance with FDA standards and supports the acceleration of its ANDA product approval process in the US [1] Group 1 - Shuo De Pharmaceutical successfully passed its second FDA on-site inspection, marking the first inspection of its nasal spray production line [1] - The inspected product is Naloxone Hydrochloride Nasal Spray, with FDA FEI number 3018360274 [1] - The successful inspection reflects the company's adherence to production management quality systems and regulatory compliance, facilitating the implementation of its internationalization strategy [1]

成都苑东生物制药股份有限公司 关于自愿披露全资子公司硕德药业通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688513 证券简称：苑东生物 公告编号：2025-080 FDA FEI：3018360274 成都苑东生物制药股份有限公司（以下简称"公司"）全资子公司成都硕德 药业有限公司（以下简称"硕德药业"）分别于 2025 年 5 月 6 日至 9 日、5 月 16 日至 22 日接受了来自美国食品药品监督管理局（以下简称"FDA"）的现行药品 生产质量管理规范（cGMP）现场检查和生物研究监测（BIMO）现场检查，系 盐酸纳洛酮鼻喷剂的批准前检查。 近日，硕德药业收到美国 FDA 出具的两份现场检查报告（即 EIR， Establishment Inspection Report），硕德药业以零缺陷（no 483）通过了上述现场 检查。现就相关情况公告如下： 一、本次检查的基本情况 检查事由：药品批准前检查（ PAI） 涉及产品：盐酸纳洛酮鼻喷剂 涉及生产线：鼻喷剂生产线 ...

Core Viewpoint - The company has successfully passed the FDA's cGMP and BIMO inspections for its product, Naloxone nasal spray, which is expected to expedite the approval process for its ANDA products in the U.S. market and support its internationalization strategy [1] Group 1 - The company's wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., underwent FDA inspections from May 6 to 9 and May 16 to 22, 2025 [1] - The inspections resulted in a "zero defect" outcome (no 483), indicating compliance with FDA standards in production management quality systems and operational compliance [1] - The positive inspection results are anticipated to accelerate the approval timeline for the company's ANDA products in the U.S. [1]

Market Overview - The A-share market experienced an overall increase on November 25, with the Shanghai Composite Index closing at 3870.02 points, up 0.87%, the Shenzhen Component Index at 12777.31 points, up 1.53%, and the ChiNext Index at 2980.93 points, up 1.77% [2] - The total trading volume in the A-share market reached 18263.21 billion yuan, an increase of 857.47 billion yuan compared to the previous trading day [2] Capital Flow - The net inflow of main funds in the A-share market for the day was 88.12 billion yuan, with an opening net inflow of 60.91 billion yuan and a closing net outflow of 1.51 billion yuan [3] - The net inflow of main funds for the CSI 300 was 49.46 billion yuan, for the ChiNext it was 20.13 billion yuan, and for the STAR Market it was 5.37 billion yuan [5] Sector Performance - The electronics sector led the net inflow of funds with 48.57 billion yuan, followed by the banking sector with 45.45 billion yuan and the non-ferrous metals sector with 42.08 billion yuan [7] - The top five sectors with net inflows included electronics, banking, non-ferrous metals, media, and communications, while the sectors with net outflows included defense, automotive, machinery, agriculture, and food and beverage [8] Stock Highlights - The stock "阳光电源" (Sungrow Power Supply) saw the highest net inflow of main funds at 10.87 billion yuan [9] - Institutions showed significant interest in several stocks, with "航天发展" (Aerospace Development) receiving a net buy of 147.16 million yuan [11] Institutional Focus - Recent institutional ratings highlighted stocks such as "梅花生物" (Meihua Biological) with a target price of 13.44 yuan, indicating a potential upside of 31.51% from its latest closing price of 10.22 yuan [13] - Other stocks of interest included "顺丰控股" (SF Holding) with a target price of 55.22 yuan, suggesting a 40.69% upside from its current price [13]

Core Viewpoint - Yuan Dong Biological announced on November 24 that the company will disclose the number of shareholders at specific points in time in its periodic reports [2] Group 1 - The company will provide updates on shareholder numbers in its regular financial disclosures [2]

Market Overview - The A-share market experienced a slight increase on November 24, with the Shanghai Composite Index closing at 3836.77 points, up 0.05%, the Shenzhen Component Index at 12585.08 points, up 0.37%, and the ChiNext Index at 2929.04 points, up 0.31%. The total market turnover was 17,405.74 billion yuan, a decrease of 2,433.32 billion yuan from the previous trading day [1]. Capital Flow - The main capital flow in the A-share market showed a net outflow of 130.24 billion yuan for the day, with an opening net outflow of 107.71 billion yuan and a tail-end net inflow of 14 billion yuan [2]. - The CSI 300 index saw a net outflow of 36.41 billion yuan, while the ChiNext and STAR Market experienced net outflows of 59.56 billion yuan and 18.45 billion yuan, respectively [4]. Sector Performance - Among the 18 sectors, the computer industry led with a net inflow of 107.91 billion yuan, reflecting a 3.12% increase [6][7]. - The top five sectors with net inflows included: - Computer: 107.91 billion yuan - Defense and Military: 106.10 billion yuan - Media: 73.98 billion yuan - Semiconductor: 62.48 billion yuan - Machinery: 36.93 billion yuan - Conversely, the sectors with the largest net outflows were: - Basic Chemicals: -26.11 billion yuan - Utilities: -16.73 billion yuan - Food and Beverage: -14.91 billion yuan - Banking: -14.07 billion yuan - Agriculture, Forestry, Animal Husbandry, and Fishery: -12.45 billion yuan [7]. Institutional Activity - Institutional investors showed interest in several stocks, with notable net purchases in stocks like Dazhong Mining and Delijia, while stocks like Vision China saw net selling [9][10]. - The latest institutional focus included stocks such as: - Fangsheng Pharmaceutical: Target price 16.60 yuan, current price 11.34 yuan, upside potential 46.38% - Xianheng International: Target price 22.36 yuan, current price 17.98 yuan, upside potential 24.36% - Huasheng Group: Target price 10.00 yuan, current price 7.49 yuan, upside potential 33.51% [11].